introduction
The concept of neurodegenerative disease is of surprisingly recent origin. Before the 20 th century, diseases of the nervous system were generally classified by symptoms (e.g., as apoplexy, epilepsy, or palsy) or according to the neuroanatomical site affected. [1] Degeneration, when used in a medical context, commonly referred to a "degenerative constitution" characterized by heritable physical, intellectual, and moral defects. [2] Over time, the term has come to be used to describe progressive deterioration in the structure and function of any tissue.
Despite infectious, inflammatory, nutritional, toxic and other causes of neurologic disease eventually being recognized, the etiology of some disorders remained elusive. These include a group of conditions, first described in the roughly one century between Parkinson's (1817) and Alzheimer's (1906) groundbreaking reports, which share several features: A chronic and relentlessly progressive course, selective involvement of particular cells and sites in the nervous system leading to distinctive symptomatology, characteristic neuropathological stigmata (e.g., intracellular inclusions or extracellular deposits), clinical presentation in later life, and the absence of effective treatment.
In recent years, this stereotypic picture of neurodegenerative disease has required modification. In some cases, a genetic (Huntington's disease) or infectious (iatrogenic and variant Creutzfeldt-Jakob disease) cause has been identified. Shared neuropathologic features and clinical concurrence have led some to view neurodegenerative disease as a continuum rather than a collection of discrete entities. [3] In addition, common molecular mechanisms, including protein misfolding and aggregation and cell-to-cell transmission, may point to a unifying pathophysiology. [4] Finally, reasonably effective if not entirely satisfactory or curative treatment is sometimes available, notably for Parkinson's disease.
The thesis of this review is that the concept of neurodegenerative disease has had heuristic value in understanding disease interrelationships, pathophysiology and etiology and that a similar construct may be usefully applied to chronic vascular disease, or "vasodegeneration."
autoimmune (multiple sclerosis, paraneoplastic), nutritional, toxic, traumatic (chronic traumatic encephalopathy), peripheral nerve, and muscle (muscular dystrophies) diseases.
If neurodegenerative disease, defined in this manner, represents a somewhat arbitrary and changeable grouping, at least it conveys a meaning that is generally understood by clinicians and researchers. In contrast, PubMed searches for "vasodegenerative disease" or "vasodegeneration" yield six or fewer citations each, so these terms are not in common use. Nevertheless, by analogy to neurodegenerative disease and neurodegeneration, they may be useful concepts. As in the case of neurodegenerative disease, defining vasodegenerative disease is discretionary. This review will focus on vascular disease associated with three common pathologic processes: atherosclerosis, hypertension, and diabetes. Immune-mediated (vasculitis), infectious (malaria), toxic (ergot alkaloids), dysplastic (fibromuscular dysplasia), and traumatic (dissection) disorders will not be considered.
unknown Etiology
The term neurodegenerative disease has often been equated with disorders of the nervous system without a known cause. Clearly this is a moving target as causes of some, especially infectious and genetic, diseases become apparent. Examples include neurosyphilis, Creutzfeldt-Jakob disease, and Huntington's disease. What qualifies as "known" etiology may be arguable, however. In Huntington's disease, for example, the gene defect is known, but how it produces the disease phenotype is poorly understood.
The causes of atherosclerosis, hypertension, and diabetes are identified to some extent and in some cases (e.g., genetic hyperlipoproteinemias, kidney disease, and anti-islet cell antibodies) are clear. However, the pathophysiologic link between even such underlying defects and their adverse effects on blood vessels is cryptic. Atherosclerotic, hypertensive, and diabetic vascular disease is commonly thought to be triggered by endothelial dysfunction, which is manifested by impaired vasoregulatory, antithrombotic, anti-inflammatory, and antiproliferative effects. [5] Such dysfunction can be observed clinically as an impairment in endothelium-dependent, nitric oxide (NO)-mediated vasodilation, which can be detected by temporary occlusion of the brachial artery with a blood-pressure cuff, leading to reactive hyperemia when the cuff is released. Arterial blood flow in the hyperemic phase is reduced in individuals at risk for atherosclerosis [6] and in patients with hypertension [7] or diabetes. [8] However, the nature of the endothelial injury responsible for dysfunction -mechanical, biochemical, or other -is unclear in most cases. [9] risk factors Neurodegenerative and vasodegenerative diseases share a range of risk factors [ Figure 1 ], including hypertension, diabetes, hyperlipidemia, smoking, and obesity. [10, 11] Conversely, healthy diet, physical activity, and certain drugs (e.g., statins, antihypertensives, and antidiabetic drugs) may have shared protective effects. [12] [13] [14] Recognition of these risk factors and the widespread adoption of measures to counteract them has coincided with a reduced incidence of both cardiovascular [15] and neurodegenerative [16] diseases.
How these various risk factors exert their effects is uncertain, and some effects on neurodegenerative disease may be mediated indirectly through the vascular system, and vice versa. Vascular changes, including defects in the blood-brain barrier and impaired clearance of β-amyloid, have been implicated by some in the pathogenesis of Alzheimer's disease [17] and other neurodegenerative disorders. [18] Conversely, autonomic dysfunction is a feature of several neurodegenerative diseases (e.g., synucleinopathies) and may accelerate atherosclerosis in some patients. [19] chronic progrEssion Degeneration implies deterioration over time, in which sense degenerative diseases are necessarily at least subacute, and usually chronic. They are also progressive, rather than static, in contrast to the fixed chronic deficits produced by monophasic insults such as trauma or infarction. For several neurodegenerative diseases, the disease process begins long before the onset of symptoms, and detectable loss of function at the clinical level typically lags years, if not decades, behind histological stigmata of disease [ Figure 2 ]. In Parkinson's disease, for example, classic signs of extrapyramidal motor dysfunction appear only after about one-third of dopaminergic neurons in the substantia nigra are lost. [20] Moreover, neuronal loss is preceded by loss of synapses and synaptic loss by depletion of dopaminergic markers, so the preclinical course is probably even more protracted than was formerly suspected. In addition, nonmotor deficits in Parkinson's disease -such as anosmia, sleep disturbances, and dysautonomia -antedate motor deficits, pushing the likely onset of disease back even further in time. The nervous system and cardiovascular system are susceptible to some of the same pathologic processes, such as atherosclerosis, hypertension and diabetes. In turn, these systems can exert reciprocal pathogenic effects, such as that of ischemia on the brain or of autonomic dysfunction on the vasculature Alzheimer's disease is another case in which a long preclinical phase is now recognized. Extracellular amyloid plaques and intracellular neurofibrillary tangles, which are characteristic histopathological features of the disease at autopsy, first appear in the brain many years before the clinical onset of disease [ Figure 3 ]. [21] Although the precise role of these deposits in pathogenesis is debated, their gradual accumulation suggests an ongoing process for which they serve at least as markers. Additional preclinical markers of Alzheimer's disease or its prodrome are detectable by brain imaging and in cerebrospinal fluid. [22] Vasodegenerative diseases also exhibit a chronic progressive course in which a long preclinical phase precedes clinical manifestations. Although myocardial infarction, stroke, and peripheral vascular disease usually present clinically in middle or late life, preclinical harbingers of vasodegeneration are detectable much earlier [ Figure 3 ]. [23] For example, early atheromatous lesions (fatty streaks) produced by adhesion and subendothelial migration of circulating monocytes, intramural accumulation of lipids, and engulfment of lipids by monocyte-derived macrophages, are found at autopsy in large muscular arteries as early as childhood. [23] In essential hypertension, which is more amenable than atherosclerosis to early clinical recognition, end-organ damage indicative of chronic vascular disease is nevertheless already apparent at diagnosis, even in children and adolescents, as demonstrated by left ventricular hypertrophy, albuminuria, and increased carotid intima-media thickness. [24] Finally, diabetic retinopathy, the most common microvascular sequela of diabetes can be detected by fundoscopy long before the onset of symptoms. [25] systEms disEasE
In many instances, neurodegenerative disorders can be viewed as "systems diseases," in that they tend to involve functionally related sites in the nervous system. Thus, Parkinson's disease and Huntington's disease affect primarily extrapyramidal motor pathways, and the autosomal dominant ataxias disrupt the cerebellum and its connections. Some neurodegenerative diseases affect multiple functional systems in combination, as in ALS, which targets both the pyramidal system and lower motor neurons, and multiple systems atrophy, in which both extrapyramidal motor and autonomic neurons degenerate. The basis for this functional selectivity is unclear and likely relates to a combination of cell-autonomous and circuitry-determined vulnerability.
The vascular system can also be seen as comprising different functional systems: The arteries, capillaries and veins, and the arteries can be further subdivided into large (elastic), medium-sized (muscular, distributing), and small (muscular, resistance) arteries, and arterioles. Like neurodegenerations, vasodegenerative diseases show differential effects on these functional systems [ Figure 4 ]. Thus, atherosclerosis occurs most prominently in large-and medium-sized arteries; [26] hypertension is associated with changes in small arteries and arterioles; [27] and diabetes involves a combination of large and medium-sized arteries (exacerbating atherosclerosis and thereby contributing to ischemic heart disease, stroke, and peripheral vascular disease) and small arteries and arterioles (resulting in retinopathy, nephropathy, and neuropathy). [28] The selective involvement of functional systems observed in some neurodegenerative and vasodegenerative diseases can also be seen in other neurologic and vascular disorders. Examples include combined systems disease due to vitamin B 12 deficiency, which affects descending motor (corticospinal) and ascending sensory (posterior columns) tracts in the spinal cord, and vasculitis, which can involve large (e.g., giant cell arteritis), medium-sized (e.g., polyarteritis), or small (e.g., Wegener's granulomatosis) arteries.
rEgional sElEctivity
Within affected functional systems, neurodegenerative diseases show predilection for particular sites or regions of involvement. Accordingly, both Parkinson's disease and Huntington's disease affect the extrapyramidal motor system, but the former primarily involves the substantia nigra and the latter the caudate nucleus and putamen, respectively. ALS affects the motor system but can do so in a variety of patterns, reflecting the involvement of upper motor neurons in cerebral cortex, lower motor neurons in the brainstem, and lower motor neurons in the spinal cord in diverse combinations. [29] Motor involvement may also be accompanied by cognitive impairment due to concurrent frontotemporal lobar degeneration.
Regional selectivity in vasodegenerative disease is especially prominent for atherosclerosis [ Figure 5 ]. Atherosclerosis is a multifocal disease that preferentially affects arterial branch points and curvatures, where physiological patterns of laminar blood flow are altered. [30] When this occurs, shear stress on the luminal surface is reduced below, or increased above, normal limits. Endothelial cells sense such alterations in shear stress, which are translated into phenotypic changes that include diminished production of NO by endothelial NO synthase. This leads to endothelial dysfunction with defects in NO-mediated vasodilatory, antithrombotic, anti-inflammatory, and antiproliferative effects that normally help to confer atheroresistance. [31] Thus, sites of disordered blood flow become more susceptible to local infiltration by circulating monocytes, accumulation of circulating lipoproteins, proliferation of vascular smooth muscle cells, and eventually plaque formation.
As its relationship to disordered flow would predict, atherosclerosis affects certain sites in the arterial tree with the highest frequency, namely sites of branching or curvature. These include the coronary arteries, aortic arch, and its branches (innominate, carotid and subclavian arteries), visceral (especially renal) branches of the abdominal aorta, and terminal abdominal aorta and its (iliac) branches. [26] The connection between flow disturbance and susceptibility to atherosclerosis is further apparent when focusing on specific vessels. For example, at the carotid bifurcation, plaque formation is most pronounced along the outer wall of the carotid sinus, which experiences especially low and oscillating shear stress, due to changes in flow caused by the combination of divided flow at the bifurcation and bulbous enlargement of the artery [ Figure 6 ]. [32] Athero-susceptibility at such sites increases further as the encroachment of plaque on the vessel lumen increasingly disorders blood flow.
In essential hypertension, the preferential involvement of small arteries and arterioles is thought to result from their reflexive, autoregulatory myogenic (contractile) response to increased intraluminal blood pressure. [33] When sustained, this response triggers smooth muscle cell migration, vessel-wall thickening, and encroachment on the lumen (inward eutrophic remodeling), which results in vessel narrowing. In large, elastic arteries, where such a contractile response to hypertension is lacking, increased blood pressure is countered by smooth muscle cell hypertrophy (outward hypertrophic remodeling), and the luminal diameter remains unchanged. Each of these remodeling strategies acts to normalize circumferential stress on the vessel wall, which is proportional to luminal radius divided by wall thickness. [34] Just as hemodynamic factors render certain sites in the arterial tree more atherosensitive, the same is true in hypertension. End organ damage from hypertension is especially common in the kidney, brain and heart, which exhibit high pulsatile blood flow and highly autoregulated vasculature. [35, 36] Macrovascular complications of diabetes are related to exacerbation of atherosclerosis, [37] so their distribution is governed by the same hemodynamic factors that confer athero-susceptibility.
Additional, nonhemodynamic, factors, may also contribute to regional selectivity in vasodegenerative diseases. For example, the differential sensitivity of large elastic and medium-to-small muscular arteries to hypertension may be influenced by intrinsic differences in basal NO production. [38] Another possibility is that regional susceptibility (or resistance) of the vasculature to degenerative disease may be determined partly by differential expression of homeobox genes in one or more cell lineages. [39] This would be consistent with the finding that atheroresistant (thoracic) aorta segments transplanted into the atherosusceptible (abdominal) aorta, and atherosusceptible (abdominal) aorta segments transplanted into the atheroresistant (thoracic) aorta, retain the atherosensitivity of their sites of origin. [40] A similar proposal regarding homeobox genes has been made in the case of neurodegenerative disease. [41] cEll-typE spEcificity Selective vulnerability of specific neuronal populations to particular neurodegenerative diseases is an overarching theme of classical neuropathology. Thus, dopaminergic neurons of the substantia nigra pars compacta, medium-sized spiny neurons in the caudate nucleus and putamen, upper and lower motor neurons, and cerebellar Purkinje cells are prototypical targets in Parkinson's disease, Huntington's disease, ALS, and spinocerebellar ataxias, respectively. An analogy can be made to vasodegenerative disease, in which the early occurrence of endothelial dysfunction points to endothelial cells as the primary site of pathology. [5, 31] Nevertheless, it is now recognized that neurons are not involved exclusively in neurodegenerative diseases, and that other cell types have important roles [ Figure 7] . In a mouse model of hereditary ALS, for example, solely neuronal expression of the mutant gene is insufficient to produce the disease. [42] Astrocytes from patients with ALS are toxic to wild-type neurons in culture, [43] and the mouse model of the disease is attenuated in chimeric ALS mice with 25%-30% wild-type nonneuronal cells. [44] Nonneuronal cells -including astrocytes, microglia, and endothelial cells -have also been implicated in the pathogenesis of Alzheimer's disease. [45] Finally, the vital part that innate and adaptive immune responses play in neurodegeneration places additional emphasis on the role of nonneuronal cells. [46] Although vasodegenerative diseases may initially target endothelial cells, they, like neurodegenerative diseases, involve additional cell types. In atherosclerosis, these include circulating monocytes that infiltrate the vessel wall, intramural monocyte-derived macrophages that internalize and are ultimately destroyed by lipid deposition, smooth muscle cells that proliferate and migrate to the intima, and platelets that adhere to sites of intimal damage. [47] Smooth muscle cells are also important mediators of hypertensive vascular disease, in which they generate myogenic responses to increased blood pressure that trigger vascular remodeling. [33] As observed for neurodegeneration, the panoply of cell types involved in innate and adaptive immunity are also implicated in atherosclerosis and other vasodegenerative diseases. [48] Thus, both neurodegeneration and vasodegeneration may target specific cell types initially or primarily, but additional resident and migrating cell populations, including those that subserve inflammation, ultimately participate as well.
dEposits and inclusions
Amyloids -misfolded proteins in β-sheet conformation that associate to form insoluble aggregates -appear to play an important role in the pathogenesis of many neurodegenerative diseases, which are therefore sometimes referred to as "proteinopathies" [ Table 1 ]. [49] In some cases, as described originally for prion diseases, these proteins are self-propagating, which fosters disease progression. [50] In addition to their proposed role in pathogenesis, protein aggregates sometimes produce characteristic intracellular inclusions or extracellular aggregates that are useful for histological diagnosis.
The presence of extracellular and intracellular lipid deposits in the atherosclerotic vessel wall is well documented, [51] Figure 7: Primary (top) and secondary (bottom) cell types targeted in neurodegenerative and vasodegenerative diseases but the role of misfolded proteins and protein aggregates in most vasodegenerative diseases is less clear. Deposits of such proteins are observed in "protein elimination failure angiopathies" associated with cerebral amyloid angiopathy, prion angiopathy, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. [52, 53] Amyloid derived largely from apolipoproteins is also found in the media of atherosclerotic arteries, where it may promote inflammation and the propensity of plaques to rupture. [54] [55] [56] Factors that could contribute to amyloid deposition in atherosclerotic arteries include the increased influx of apolipoproteins, their oxidative modification, the cytotoxic, and pro-inflammatory effects of foam cell-derived cholesterol crystals, [57] and dysfunction of the ubiquitin-proteasome system; the latter may be related to substrate overload from the combined demands of lipid metabolism, production of foam cells from macrophages, and proliferation and migration of vascular smooth muscle cells. [58] In this respect, atherosclerosis has been likened to other "protein quality" diseases, including neurodegenerations. [59] contiguous sprEad Several neurodegenerative diseases are associated with cell-to-cell (prionic) transmission, which allows them to spread through the central nervous system, producing characteristic anatomical patterns of pathology. [4, 60] This was shown originally for prion diseases but is now thought to occur in most if not all neurodegenerative proteinopathies. [61] Disease spread involves the release of misfolded pathogenic proteins -in naked form or packaged in vesicles -from affected neurons, or their direct transfer to adjacent neurons through nanotubes. In the former case, extracellular proteins are then taken up by neighboring neurons through endocytosis, pinocytosis, or fusion of vesicles with the cell membrane. Extracellular vesicles, which include exosomes (30-100 nm) and microvesicles (100/nm µm) and participate in normal interneuronal signaling, may, therefore, have a pivotal role in the pathogenesis of neurodegenerative disease. [62] Although neurodegenerative diseases have long been known to initially involve preferentially vulnerable neuronal populations and to worsen over time, only recently have the patterns and mechanisms of this worsening been focused on. Two general patterns of disease spread have been recognized: contiguous propagation, which affects anatomically adjacent areas and does not require synaptic connectivity, and network propagation, which involves synaptically (and therefore functionally) connected, and sometimes distant, regions. [63] These two modes of transmission are not mutually exclusive. In ALS, for example, increasing involvement of a single limb could represent contiguous propagation to neighboring motor neurons within the anterior horn of the spinal cord, whereas the addition of upper to lower (or lower to upper) motor neuron symptoms might reflect network propagation. Whereas ALS may begin in any limb and as either upper or lower motor neuron disease and progress in seemingly random fashion, most neurodegenerative disorders evolve more stereotypically. [61] In Alzheimer's disease, β-amyloid pathology spreads centripetally from cerebral cortex to subcortical regions, while tau pathology moves in the opposite direction, from brainstem and entorhinal cortex to neocortex. In Parkinson's disease, α-synuclein deposits are seen first in the brainstem and olfactory bulb and ascend from there to the neocortex.
Like neurodegeneration, vasodegenerative disease first affects preferentially vulnerable sites and then spreads. In atherosclerosis, this may involve gradual, nonstenosing lateral extension of plaques. [64] Alternatively, with focal stenosing disease, impingement of an atherosclerotic plaque on the vascular lumen alters local hemodynamics, resulting in increased shear stress at the upstream (trailing) edge, and decreased shear stress at the downstream (leading) edge. [65] As a result, upstream regions of the plaque become more vulnerable to rupture, while the plaque grows distally, where it is now exposed to the low-shear conditions that contributed to its onset. The molecular mechanisms underlying plaque extension are unclear. However, in a mouse model of atherosclerosis, vascular endothelial growth factor increased aortic plaque area and circumference, which may be due to increased vascular permeability, altered expression of adhesion molecules, monocyte chemotaxis, mobilization of macrophages from bone marrow, or vasa vasorum angiogenesis. [66, 67] In a similar model, depletion of oxidized low-density lipoprotein (oxLDL) decreased plaque extension in the aorta, and this was accompanied by reduced accumulation of oxLDL in plaques and diminished infiltration of plaques with T lymphocytes and macrophages. [68] Thus, in atherosclerosis as in neurodegeneration, extension of disease appears to involve the same messengers and mechanisms implicated in disease onset.
In vasodegeneration, as in neurodegeneration, extracellular vesicles may also contribute to the spread of disease. This need not involve the transmission of aberrant proteins, as normal proteins and nucleic acids, including microRNAs, can be conveyed in this manner as well. Circulating levels of endothelium-and other vascular cell-derived extracellular vesicles are increased in patients with atherosclerosis, hypertension and diabetes, and correlate with the severity of associated vascular pathology. [69, 70] In atherosclerosis, extracellular vesicles can interact with endothelial cells to impair NO-mediated vasoprotection, which could extend the area susceptible to atherogenesis. [71, 72] A similar situation may exist for diabetic macroangiopathy, whereas angiogenic effects of extracellular vesicles could contribute to diabetic microangiopathy (e.g., retinopathy). [73, 74] Angiotensin II has been shown to stimulate the release of prothrombotic vesicles from human monocytes, possibly providing an additional link between hypertension and vasculopathy. [75] Although the extent to which extracellular vesicles are participants in, and not just markers of, vascular disease is uncertain, these observations highlight the potential for a shared role in neurodegeneration and vasodegeneration.
agE-rElatEdnEss
Neurodegenerative and vasodegenerative diseases have both been described as "diseases of aging." Such classification may be useful clinically in informing the differential diagnosis of neurologic or cardiovascular disease presenting in the elderly. However, as noted before, the pathologic process that leads to clinical involvement in most of these conditions begins well before advanced age, and sometimes in childhood. In addition, neurodegenerative and vasodegenerative disease can present in early or mid-life, as in genetic dyslipidemias or Huntington's disease. Rather than being related by aging, therefore, neurodegenerative and vasodegenerative diseases may be more accurately considered to be related by age at presentation. That is, both forms of degeneration progress over many years, so they tend to reach clinical expression in later life.
conclusions
Recent advances in our understanding of neurodegenerative and vasodegenerative diseases have occurred more or less in parallel, with little consideration of their common features.
These include their complex etiology, shared risk factors, chronic progressive course, preferential geographic and cellular patterns of involvement, extracellular deposits and intracellular inclusions, time-dependent spread, and typical clinical presentation in later life. Recognizing the similarities between neurodegeneration and vasodegeneration may encourage the cross-application of future developments between the two fields of study.
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